|
|
|
|
|
| The diagnostic value of serum miRNA-155-5p, miRNA-133a-3p for myocardial injury in sepsis |
| Cai Hua-zhong, Qin Xiao-meng, Zhou Feng, Miao Zhen-jun, Wang Yan, Jia Yu, Ren Guo-qing |
| Department of Emergency Medicine Center, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China |
|
|
|
|
Abstract Objective To evaluate the diagnostic value of serum miRNA-155-5p, miRNA-133a-3p for myocardial injury in sepsis. Methods Septic patients admitted to the hospital were divided into control group ( n =48) and myocardial injury group ( n =40) according to cardiac ultrasound. The level of serum miRNA-155-5p and miRNA-133a-3p were also detected. The diagnostic value of the level of serum miRNA-155-5p and miRNA-133a-3p was analyzed by ROC curve. Results Compared with the control group, the expression levels of serum miRNA-155-5p［(2.02±0.45) vs. (2.89±0.37)］and miRNA-133a-3p［(1.93±0.37) vs. (2.42±0.22)］ in patients with myocardial injury of sepsis were significantly increased( P <0.05). ROC curve analysis indicated that detection of miRNA-155-5p (AUC=0.92, 95% CI 0.86~0.97, P =0.028, sensitivity 97.50%, specificity 72.92%) and miRNA-133a-3p (AUC=0.87, 95% CI 0.80~ 0.95 , P =0.040, sensitivity 95.00%, specificity 70.00%) were of high diagnostic value for myocardial injury in patients with sepsis. Conclusion Detection of the expression of miRNA-155-5p and miRNA-133a-3p in serum is helpful for the diagnosis of myocardial injury in sepsis.
|
|
|
| Fund:
|
|
Corresponding Authors:
Ren Guo-qing, E-mail: 534584150@qq.com
|
|
|
|
| ［1］Rhodes A, Phillips G, Beale R, et al. The surviving sepsis campaign bundles and outcome: results from the international multicentre prevalence study on sepsis (the IMPreSSstudy)［J］. Intensive Care Med, 2015, 41 (9): 1620-1628. ［2］江伟,杜斌. 中国脓毒症流行病学现状［J］. 医学研究生学报, 2019, 32 (1): 5-8. ［3］吴健锋,裴飞. 脓毒症免疫治疗的研究现状［J］. 医学研究生学报, 2019, 32 (1): 37-42. ［4］Drosatos K, Lymperopoulos A, Kennel PJ, et al. Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both ［J］. Curr Heart Fail Rep, 2015, 12 (2): 130-140. ［5］Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases［J］. RNA Biol, 2012, 9 (6): 850-859. ［6］Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis - 3)［J］. JAMA, 2016, 315 (8): 801-810. ［7］Angus DC,Van Der Poll T. Severe sepsis and septic shock［J］. N Engl J Med, 2013, 369 (21): 2063. ［8］李维勤,习丰产. 脓毒症定义和集束化治疗方案更新对当前临床实践的挑战［J］. 医学研究生学报, 2019, 32 (1): 9-13. ［9］李维勤. 脓毒症诊疗的新挑战——持续炎症、免疫抑制和分解代谢综合征［J］. 医学研究生学报, 2017, 30 (7): 673-677. ［10］Suzuki T, Suzuki Y, Okuda J, et al. Sepsis-induced cardiac dysfunction and beta-adrenergic blockade therapy for sepsis［J］. J Intensive Care, 2017, 5: 22. ［11］Vasilescu C, Dragomir M, Tanase M, et al. Circulating miRNAs in sepsis-A network under attack: an in-silico prediction of the potential existence of miRNA sponges in sepsis［J］. PLoS One, 2017, 12 (8): e0 183 334. ［12］Fernandez-Ruiz I. Cardiac regeneration: A hydrogel-miRNA complex stimulates heart recovery［J］. Nat Rev Cardiol, 2018, 15 (2): 68-69. ［13］马超,法宪恩,柳兵,等. 低能激光照射对大鼠心肌梗死后miRNA-21表达的影响［J］. 郑州大学学报(医学版), 2016,51 (3): 333-336. ［14］Kishore R, Verma SK, Mackie AR, et al. Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts［J］. PLoS One, 2013, 8 (4): e60 161. ［15］Abdellatif M. The role of microRNA-133 in cardiac hypertrophy uncovered［J］. Circ Res, 2010, 106 (1): 16-18. ［16］李达,彭卫平,沈莉, 等. miRNA-133与冠心病的关系［J］. 中国动脉硬化杂志, 2015, 23(8): 851-854. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
